Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Rodon

Showing results (81-90 of 247) with videos related to

Pageof 25
Sort By:
The Oncologist|March 17, 2021
Overview of Ocular Side Effects of SelinexorNagham Al-Zubidi, Dan S Gombos, David S Hong, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplificationEric Angevin, Gianluca Spitaleri, Jordi Rodon, et al.
Cancer Medicine|February 24, 2024
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumorsNiamh Coleman, Bettzy Stephen, Siqing Fu, et al.
Journal for Immunotherapy of Cancer|October 9, 2024
Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignanciesJoe Y Chang, Xinyan Xu, Girish S Shroff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2026
Convergence of KRAS Mutations and MTAP Loss in Pancreatic Cancer: Genomic Landscape and Clinical ImplicationsCamila Braganca Xavier, Pooja A Shah, Daria Yakimova, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2011
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancerHeather A Wakelee, Chris H Takimoto, Arturo Lopez-Anaya, et al.
Investigational New Drugs|April 24, 2015
A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancerAnalia Azaro, Jordi Rodon, Antonio Calles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor MalignanciesMelissa Johnson, Anthony El-Khoueiry, Navid Hafez, et al.
The Journal of Infectious Diseases|December 14, 2021
Rapid SARS-CoV-2 Inactivation in a Simulated Hospital Room Using a Mobile and Autonomous Robot Emitting Ultraviolet-C LightCristina Lorca-Oró, Jordi Vila, Patricia Pleguezuelos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade GliomaPatrick Y Wen, Timothy F Cloughesy, Alan G Olivero, et al.
Pageof 25

Showing results (81-90 of 247) with videos related to

Sort By:
Pageof 25
The Oncologist|March 17, 2021
Overview of Ocular Side Effects of SelinexorNagham Al-Zubidi, Dan S Gombos, David S Hong, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplificationEric Angevin, Gianluca Spitaleri, Jordi Rodon, et al.
Cancer Medicine|February 24, 2024
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumorsNiamh Coleman, Bettzy Stephen, Siqing Fu, et al.
Journal for Immunotherapy of Cancer|October 9, 2024
Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignanciesJoe Y Chang, Xinyan Xu, Girish S Shroff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2026
Convergence of KRAS Mutations and MTAP Loss in Pancreatic Cancer: Genomic Landscape and Clinical ImplicationsCamila Braganca Xavier, Pooja A Shah, Daria Yakimova, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2011
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancerHeather A Wakelee, Chris H Takimoto, Arturo Lopez-Anaya, et al.
Investigational New Drugs|April 24, 2015
A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancerAnalia Azaro, Jordi Rodon, Antonio Calles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor MalignanciesMelissa Johnson, Anthony El-Khoueiry, Navid Hafez, et al.
The Journal of Infectious Diseases|December 14, 2021
Rapid SARS-CoV-2 Inactivation in a Simulated Hospital Room Using a Mobile and Autonomous Robot Emitting Ultraviolet-C LightCristina Lorca-Oró, Jordi Vila, Patricia Pleguezuelos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade GliomaPatrick Y Wen, Timothy F Cloughesy, Alan G Olivero, et al.
Pageof 25